Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
- PMID: 29217836
- PMCID: PMC6904225
- DOI: 10.1038/nrd.2017.221
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Abstract
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene, FMR1, has been the focus of intense research. Key alterations in synaptic function thought to underlie this neurodevelopmental disorder have been characterized and rescued in animal models of FXS using genetic and pharmacological approaches. These robust preclinical findings have led to the implementation of the most comprehensive drug development programme undertaken thus far for a genetically defined neurodevelopmental disorder, including phase IIb trials of metabotropic glutamate receptor 5 (mGluR5) antagonists and a phase III trial of a GABAB receptor agonist. However, none of the trials has been able to unambiguously demonstrate efficacy, and they have also highlighted the extent of the knowledge gaps in drug development for FXS and other neurodevelopmental disorders. In this Review, we examine potential issues in the previous studies and future directions for preclinical and clinical trials. FXS is at the forefront of efforts to develop drugs for neurodevelopmental disorders, and lessons learned in the process will also be important for such disorders.
Conflict of interest statement
Competing interests statement
The authors declare
Figures
![Figure 1 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6904225/bin/nihms-1061581-f0001.gif)
![Figure 2 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6904225/bin/nihms-1061581-f0002.gif)
Similar articles
-
Emerging pharmacological therapies in fragile X syndrome and autism.Curr Opin Neurol. 2019 Aug;32(4):635-640. doi: 10.1097/WCO.0000000000000703. Curr Opin Neurol. 2019. PMID: 31045620 Review.
-
Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome.Platelets. 2018 Mar;29(2):113-124. doi: 10.1080/09537104.2017.1317733. Epub 2017 Jun 29. Platelets. 2018. PMID: 28660769 Review.
-
Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.Pediatr Neurol. 2014 Apr;50(4):297-302. doi: 10.1016/j.pediatrneurol.2013.12.001. Epub 2013 Dec 4. Pediatr Neurol. 2014. PMID: 24518745 Review.
-
Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome.J Child Adolesc Psychopharmacol. 2017 Dec;27(10):850-863. doi: 10.1089/cap.2016.0200. Epub 2017 May 5. J Child Adolesc Psychopharmacol. 2017. PMID: 28475355 Review.
-
Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.Curr Pharm Des. 2015;21(34):4972-4979. doi: 10.2174/1381612821666150914121038. Curr Pharm Des. 2015. PMID: 26365141 Free PMC article. Review.
Cited by
-
Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research.J Clin Invest. 2024 Mar 1;134(5):e175036. doi: 10.1172/JCI175036. J Clin Invest. 2024. PMID: 38426491 Free PMC article.
-
Characterising the behaviours in most severe and least severe emotional outbursts in young people.Sci Rep. 2024 Feb 5;14(1):2957. doi: 10.1038/s41598-024-52732-x. Sci Rep. 2024. PMID: 38316883 Free PMC article.
-
A novel combination treatment for fragile X syndrome predicted using computational methods.Brain Commun. 2024 Jan 15;6(1):fcad353. doi: 10.1093/braincomms/fcad353. eCollection 2024. Brain Commun. 2024. PMID: 38226317 Free PMC article.
-
Intermittent Hypobaric Hypoxia Ameliorates Autistic-Like Phenotypes in Mice.J Neurosci. 2024 Feb 14;44(7):e1665232023. doi: 10.1523/JNEUROSCI.1665-23.2023. J Neurosci. 2024. PMID: 38124211
-
iBehavior-a preliminary proof of concept study of a smartphone-based tool for the assessment of behavior change in neurodevelopmental disabilities.Front Psychol. 2023 Oct 18;14:1217821. doi: 10.3389/fpsyg.2023.1217821. eCollection 2023. Front Psychol. 2023. PMID: 37920743 Free PMC article.
References
-
- Oberle I et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252, 1097–1102 (1991). - PubMed
-
- Pieretti M et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817–822 (1991). - PubMed
-
References and are seminal papers of the simultaneous discovery of FMR1 by several research groups.
-
- Handt M et al. Point mutation frequency in the FMR1 gene as revealed by fragile X syndrome screening. Mol. Cell Probes 28, 279–283 (2014). - PubMed
-
- Dykens EM, Hodapp RM & Leckman JF Strengths and weaknesses in the intellectual functioning of males with fragile X syndrome. Am. J. Ment. Defic 92, 234–236 (1987). - PubMed
-
- Fisch GS et al. Longitudinal changes in cognitive-behavioral levels in three children with FRAXE. Am. J. Med. Genet 84, 291–292 (1999). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical